Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-06-13
DOI
https://doi.org/10.1200/jco-25-00183
Citations
2
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
4.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study

Adèle de Masson, M. Beylot‐Barry, Samia Mourah, Jacques Rouanet et al.
2 citations
Journal of Clinical Oncology
Cutaneous lymphoproliferative disorders research
4.01
article

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study

Adèle de Masson, M. Beylot‐Barry, Samia Mourah, Jacques Rouanet, Sébastien Maury, Michael L. Loschi, Aline Schmidt-Tanguy, O. Dereure, Jean-Baptiste Méar, S. Boulinguez, Marc Bernard, Roch Houot, Henri Adamski, Anne Huynh, Étienne Daguindau, David Michonneau, Amandine Charbonnier, F. Aubin, Jérôme Cornillon, Hélène Moins‐Teisserenc, G. Chaby, Patrice Céballos, Sylvie Chevret, Emmanuel Bachy, Florent Grange, Yannick Le Corre, M. Bagot, Stéphane Barète, Stéphane Dalle, Régis Peffault de Latour, Maxime Battistella, C. Ram‐Wolff, Ambroise Marçais, Anne Pham‐Ledard, Hélène Labussière‐Wallet, Katayoun Jondeau, Laurence Michel, Édouard Forcade, Corentin Orvain, Stéphanie Nguyen, Pauline Brice, Jean-David Bouaziz, Nathalie Franck, Gérard Socié, E. Wierzbicka-Hainaut, Julie Abraham, Christine Longvert, Marie-Thérèse Rubio, Alexandra Picard, Natacha Maillard, Saskia Ingen-Housz-Oro, Jacques-Olivier Bay
article en
2 citations

Abstract

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.

Journal of Clinical OncologyVol. 43(22)
Centre National de la Recherche Scientifique (FR), Université de Bordeaux (FR), Inserm (FR), Université Paris-Est Créteil (FR), Université de Montpellier (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Nice (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), Centre Hospitalier Universitaire de Toulouse (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR), Hôpital Cochin (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre Hospitalier Universitaire d'Angers (FR), Hôpital Nord (FR), Centre Hospitalier Universitaire de Limoges (FR), Pitié-Salpêtrière Hospital (FR), Hôpital Pontchaillou (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpital Ambroise-Paré (FR), Centre Hospitalier de Valence (FR), Hôpital Saint-Louis (FR), Ingénierie Moléculaire et Physiopathologie Articulaire (FR), Centre Hospitalier Universitaire de Rennes (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Institut de recherche Saint-Louis (FR), BoRdeaux Institute of onCology (FR), Université d'Angers (FR), Université de Rennes (FR), Université de Lorraine (FR), Nantes Université (FR)
National Cancer Institute
Good health and well-being
Openalex Percentile: Top 7%
Cutaneous lymphoproliferative disorders research
4.01
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.